| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3235 |
| Trial ID | NCT05618041 |
| Disease | Lymphoma | Acute Lymphoblastic Leukemia | Multiple Myeloma |
| Altered gene | CD19|CD20|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD19/CD20 CAR-T cells |
| Recruitment status | Recruiting |
| Title | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies |
| Year | 2022 |
| Country | China |
| Company sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Other ID(s) | 20221019 |
| Cohort 1 | |||||||||||
|
|||||||||||